According to Frost & Sullivan’s (2013), Global Pharmaceutical Contract Manufacturing Market – report, injectable drug development will be a main growth driver over the next few years as the pharmaceutical industry continues to focus on oncology and treatment with cytotoxic drugs in particular. Symbiosis CEO Colin MacKay said “We are seeing a similar trend. A large proportion of our customers work within oncology and many are interested in our ability to safely manufacture cytotoxics and ADCs (Antibody Drug Conjugates) for clinical trials”.
Symbiosis specialises in the sterile, GMP manufacture of novel, injectable pharmaceuticals (including cytotoxic, conventional and biologics) for use in clinical trials.
Source: Frost &Sullivan (2013) Injectable Drugs to Drive CMO Growth. [Online] Available at:http://www.fiercepharmamanufacturing.com/story/injectable-drugs-drive-cmo-growth/2013-08-29?utm_campaign= SocialMedia [Accessed on 12 September 2013]